Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Over-reaction Reigns At Rigel And Biogen

Executive Summary

Rigel and Biogen both released data last week that prompted over-reactions and sensationalism, respectively from analysts, the print media and even the BBC. When something sounds too good to be true, is probably is.

You may also be interested in...



Stockwatch: Oscillating fortunes

For some companies reporting their second-quarter earnings, last week was one of fluctuating fortunes. What the market gave to their share prices on one day it took away the next, and running through earnings season was that consistently big subtraction – the effect of foreign currency translations – and the concern that it may yet accelerate.

Stockwatch: Biogen's belligerent repetition

Two iconic artists are brought together in unlikely combination at an exhibition that opens in Oxford this week. The patterns of William Morris's curtains and wallpapers have a sublime connection with Andy Warhol's prints of Marilyn Monroe – repetition. The theme of repetition also struck me in the most impactful clinical data release of last week.

Stock Watch: Risk And The Pharmaceutical Discount Rate

In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC097243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel